Cargando…

The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The pathological hallmark of PD is the appearance of intraneuronal cytoplasmic α-synuclein (α-Syn) aggregation, called Lewy bodies. α-Syn aggregation is deeply involved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujimaki, Ayaka, Ohuchi, Kazuki, Takizawa, Shinnosuke, Murakami, Takanori, Kurita, Hisaka, Hozumi, Isao, Wen, Xiaopeng, Kitamura, Yoshihisa, Wu, Zhiliang, Maekawa, Yoichi, Inden, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511692/ https://www.ncbi.nlm.nih.gov/pubmed/37731009 http://dx.doi.org/10.1038/s41598-023-42903-7

Ejemplares similares

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
por: Chen, Nan, et al.
Publicado: (2017)

Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation
por: Miao, A-Feng, et al.
Publicado: (2021)

Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson’s Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function
por: Li, Xuan, et al.
Publicado: (2018)

Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action
por: Chang, Wei-Ting, et al.
Publicado: (2019)

Radioprotective effects of roxadustat (FG‐4592) in haematopoietic system
por: Zhang, Pei, et al.
Publicado: (2018)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

Kaempferol Has Potent Protective and Antifibrillogenic Effects for α-Synuclein Neurotoxicity In Vitro
por: Inden, Masatoshi, et al.
Publicado: (2021)

FG-4592 protects the intestine from irradiation-induced injury by targeting the TLR4 signaling pathway
por: Feng, Zhenlan, et al.
Publicado: (2022)

Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways
por: Long, Guangfeng, et al.
Publicado: (2020)

Roxadustat (FG-4592) Facilitates Recovery From Renal Damage by Ameliorating Mitochondrial Dysfunction Induced by Folic Acid
por: Li, Xue, et al.
Publicado: (2022)

Roxadustat (FG-4592) abated lipopolysaccharides-induced depressive-like symptoms via PI3K signaling
por: Li, Axiang, et al.
Publicado: (2023)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

p-Coumaric Acid Has Protective Effects against Mutant Copper–Zinc Superoxide Dismutase 1 via the Activation of Autophagy in N2a Cells
por: Ueda, Tomoyuki, et al.
Publicado: (2019)

Characteristics and Therapeutic Potential of Dental Pulp Stem Cells on Neurodegenerative Diseases
por: Ueda, Tomoyuki, et al.
Publicado: (2020)

The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model
por: Zhou, Muran, et al.
Publicado: (2019)

Osteoblast–Osteoclast Coculture Amplifies Inhibitory Effects of FG‐4592 on Human Osteoclastogenesis and Reduces Bone Resorption
por: Hulley, Philippa A, et al.
Publicado: (2020)

MicroRNA-5572 Is a Novel MicroRNA-Regulating SLC30A3 in Sporadic Amyotrophic Lateral Sclerosis
por: Kurita, Hisaka, et al.
Publicado: (2020)

The neuroprotective effects of activated α7 nicotinic acetylcholine receptor against mutant copper–zinc superoxide dismutase 1-mediated toxicity
por: Ito, Taisei, et al.
Publicado: (2020)

Stem Cells From Human Exfoliated Deciduous Teeth-Conditioned Medium (SHED-CM) is a Promising Treatment for Amyotrophic Lateral Sclerosis
por: Ueda, Tomoyuki, et al.
Publicado: (2022)

The Novel gem-Dihydroperoxide 12AC3O Suppresses High Phosphate-Induced Calcification via Antioxidant Effects in p53LMAco1 Smooth Muscle Cells
por: Takase, Naoko, et al.
Publicado: (2020)

Inhibition of HIF prolyl-4-hydroxylases by FG-4497 Reduces Brain Tissue Injury and Edema Formation during Ischemic Stroke
por: Reischl, Stefan, et al.
Publicado: (2014)

Partial reduced Pi transport function of PiT-2 might not be sufficient to induce brain calcification of idiopathic basal ganglia calcification
por: Nishii, Kazuya, et al.
Publicado: (2019)

Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3β/Nrf2 Pathway
por: Li, Xue, et al.
Publicado: (2020)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
por: Lun, Jie, et al.
Publicado: (2023)

FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models
por: Jiang, Yumin, et al.
Publicado: (2023)

Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney transplant recipients
por: Ogata, Masatomo, et al.
Publicado: (2022)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
por: Zheng, Li, et al.
Publicado: (2022)

The effects of Brazilian green propolis that contains flavonols against mutant copper-zinc superoxide dismutase-mediated toxicity
por: Ueda, Tomoyuki, et al.
Publicado: (2017)

Neuroprotective effect of 5-aminolevulinic acid against low inorganic phosphate in neuroblastoma SH-SY5Y cells
por: Takase, Naoko, et al.
Publicado: (2017)

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
por: Besarab, Anatole, et al.
Publicado: (2015)

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
por: Kiriakidis, Serafim, et al.
Publicado: (2017)

Involvement of Prolyl Hydroxylase Domain Protein in the Rosiglitazone-Induced Suppression of Osteoblast Differentiation
por: Kang, Ju-Hee, et al.
Publicado: (2015)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
por: Li, Jing, et al.
Publicado: (2022)

A Novel Prolyl Hydroxylase Inhibitor Protects Against Cell Death After Hypoxia
por: Kontani, Satoru, et al.
Publicado: (2013)

The role of HIF prolyl hydroxylases in tumour growth
por: Jokilehto, Terhi, et al.
Publicado: (2010)

Function and expression of prolyl hydroxylase 3 in cancers
por: Liu, Qiu-long, et al.
Publicado: (2013)

Loss of Endothelial Hypoxia Inducible Factor‐Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis
por: Dai, Zhiyu, et al.
Publicado: (2021)

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications
por: Kim, So Yeon, et al.
Publicado: (2015)

Use of cyclic peptides to induce crystallization: case study with prolyl hydroxylase domain 2
por: Chowdhury, Rasheduzzaman, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rph9oik9imljl9r6b6o450467o